Patient-reported symptom relief from the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
Patient satisfaction with tildrakizumab treatment in the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
Efficacy and safety of 1% clascoterone cream through 12 weeks in patients ≥12 years of age with facial acne vulgaris: pooled data analyses of two Phase 3 randomized clinical trials
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: Malignancies in the Phase 3 POETYK PSO-1, PSO-2, and Long-term Extension (LTE) Trials
Long-Term Safety of Risankizumab in Patients With Psoriatic Disease: Findings From Integrated Analyses of 17 Clinical Trials in Psoriasis and 4 in Psoriatic Arthritis
Long-term Efficacy and Safety of Risankizumab (RZB) for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Beyond 4 Years
Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial
Dupilumab treatment restores skin barrier function and improves clinical and patient reported outcomes in adults and adolescents with moderate to severe atopic dermatitis
Efficacy and Safety of Dupilumab in Children Aged 6–11 Years with Inadequately Controlled Severe Atopic Dermatitis: Results From an Open-Label Extension Trial up to 1 Year